Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches

Unlocking the potential of broadly reactive coronavirus monoclonal antibodies (mAbs) and their derivatives offers a transformative therapeutic avenue against severe COVID-19, especially crucial for safeguarding high-risk populations. Novel mAb-based immunotherapies may help address the reduced effic...

Full description

Saved in:

Bibliographic Details
Main Authors:	Daouda Abba Moussa, Mario Vazquez, Christine Chable-Bessia, Vincent Roux-Portalez, Elia Tamagnini, Mattia Pedotti, Luca Simonelli, Giang Ngo, Manon Souchard, Sebastien Lyonnais, Myriam Chentouf, Nathalie Gros, Soledad Marsile-Medun, Heiko Dinter, Martine Pugnière, Pierre Martineau, Luca Varani, Manel Juan, Hugo Calderon, Mar Naranjo-Gomez, Mireia Pelegrin
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Series:	Emerging Microbes and Infections
Subjects:	Non-neutralizing antibodies infected cell-targeting SARS-CoV-2 antibody-based therapy cell therapy CAR-T cells
Online Access:	https://www.tandfonline.com/doi/10.1080/22221751.2024.2432345
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches

Similar Items